Report Summary:
Thelansis
“Alport
Syndrome (AS) - Market outlook, Epidemiology, Market Forecast and
Competitive Landscape - 2018 To 2030 ”
this report provides a comprehensive study of the disease area landscape
and changing market dynamics with
respect to the current & future market events for the 8 MM countries
(USA, EU5, Japan & China).
The
report provides a comprehensive view of disease events, classification,
severity level, stages, identified and emerging biomarkers, progression, manifestations,
symptoms, risk factors, pathogenesis, genetic basis and treatment guidelines at
country level.
Disease overview:
Alport syndrome is an inherited
progressive form of glomerular disease that is often associated with
sensorineural hearing loss and ocular defects. The primary abnormality arises
from mutations in genes encoding the type IV collagen protein family. This
syndrome is a genetically heterogeneous disease having different mutations and
forms of inheritance: X-linked (mutations in COL4A5 gene), autosomal recessive
(homozygous or compound heterozygous mutations in COL4A3 or COL4A4 genes) and
autosomal dominant.
Epidemiology:
The total number of Alport
syndrome increased from 128,924 in 2018 to 182,305 by 2030. The USA comprises
of ~38 of the total diagnosed cases of AS followed by China, EU5 and Japan.
~80% cases had typical glomerular basement membrane (GBM) changes of AS, ~10%
patients initially had pathology features of diffuse thinning of the GBM only,
14% patients showed pathology of focal segmental glomerulosclerosis (FSGS).
Market Scenario:
Current clinical practice
recommendations for delaying end stage renal disease in patients with Alport
syndrome focus on early introduction of RAAS inhibitors to suppress urinary
protein excretion.
KOL
insights: KOLs across 8 MM
market from center of Excellence/ Public/ Private hospitals participated in the
study. Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm and Unmet needs.
Competitive Landscape:
Considering Alport syndrome is an
excellent model of CKD with proteinuria and fibrosis, orphan drug designation
with premium pricing benefits, number of patients to be treated will be
substantial and finally s no approved treatment several drug candidates are in
Phase II and II/ III stages of development by various companies.
Market
Forecasting: Thelansis’
research team expects the Alport syndrome market potential for 2030 at $X.XXB
in 8MM countries. Out of this market, 68.5% sales are expected to be contributed
from the US market whereas XX.X% is expected to come from EU-5. Japan and China
are expected to contribute XX.X% and X.X% respectively.
* Alport syndrome current market
stands at $XXXX.XM which is expected to grow from 2019 to 2024 at a CAGR of
X.X%. Majorly this is expected because of expected approvals of
pharmacotherapies in the space.
Contact Us:
About Thelansis: As the name
depicts Thelansis is specialized in “Therapy Area Landscape Analysis” along
with market intelligence and consultancy that supports pharmaceutical,
biotechnology, and diagnostics companies to successfully prepare, launch, and
commercialize their products. Our Syndicated primary market research reports
include Market Insight, Pipeline Insight, Product Insight, Specialized Reports,
Indication Outlook and Market Access Reports. Ask for our report offerings, and
Indication specific sample pages by sharing your email ID with us at, p.potdar@thelansis.com.
Peeyush
Potdar
Delivery
Head:
Email: p.potdar@thelansis.com
Visit us at http://www.thelansis.com/
Delivery office
B-1030, C
Wing
Vrindavan
tech village Marathahalli
Outer ring
road, Bangalore- 560037
Sales office
183-Asylum
Street Hartfort, CT-06103, USA
Telephone
USA +1-302-380-3552, India +91-9899921259
Email
clientsupport@thelansis.com, sales@thelansis.com
No comments:
Post a Comment